Novo Nordisk stock news
On July 31, 2026, a federal judge in New Jersey ruled that a class--action lawsuit against Novo Nordisk (NVO) may proceed, allowing investors to seek damages for significant stock losses incurred in 2024. The litigation centers on a 20% share price collapse following the disclosure of clinical trial results for the weight--loss drug CagriSema. The court's decision permits claims against the company and former executives, including ex--CEO Lars Fruergaard Jørgensen, over allegations that they misled the market regarding the drug's efficacy and commercial prospects.